Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23182426 | 1.00 | CACNA2D1 (0.55) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL7782653 | 1.00 | CACNA2D1 (0.55) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL4882397 | 0.86 | CACNA2D1 (0.57) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL28474689 | 0.86 | CACNA2D1 (0.57) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL13990313 | 0.86 | ALDH1A1 (0.44) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL18125945 | 0.86 | CACNA2D1 (0.57) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL4882396 | 0.86 | CACNA2D1 (0.57) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL28479280 | 0.85 | CACNA2D1 (0.55) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL18508446 | 0.83 | CACNA2D1 (0.53) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| SCHEMBL18508351 | 0.83 | CACNA2D1 (0.53) | CACNA2D1ADRA1ACACNB3CACNA1CPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023082003-A1 | NEW CANNABINOID-GABAPENTINOID CONJUGATES AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2023-05-19 | — | — | WO | disclosed |
| EP-3148969-B1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | KETOGEN INC (CA) | 2020-11-11 | — | — | EP | disclosed |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| WO-2015184542-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-10 | — | — | WO | disclosed |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-03 | — | — | US | disclosed |
| US-8063244-B2 | Process for the synthesis of pregabalin | DIPHARMA FRANCIS S.R.L. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-20100292506-A1 | PROCESS FOR THE SYNTHESIS OF PREGABALIN | DIPHARMA FRANCIS S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| US-20090143615-A1 | Process for the Preparation of (S)(+)-3-(Aminomethyl)-5-Methylhexanoic Acid | DIPHARMA FRANCIS S.R.L. (IT) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143615-A1 | Process for the Preparation of (S)(+)-3-(Aminomethyl)-5-Methylhexanoic Acid | HPD, ALKBH5, PAH | CACNA2D1 2993/4885ADRA1A 947/4885CACNB3 2825/4885 |
| US-20100292506-A1 | PROCESS FOR THE SYNTHESIS OF PREGABALIN | GABRB2, GABBR1, GABBR2 | CACNA2D1 126/4885ADRA1A 343/4885CACNB3 187/4885 |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | CACNA2D1 2099/4885ADRA1A 2617/4885CACNB3 933/4885 |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | CACNA2D1 2099/4885ADRA1A 2617/4885CACNB3 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.